Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Phathom Pharmaceuticals (PHAT) EBT (2022 - 2026)

Phathom Pharmaceuticals (PHAT) has disclosed EBT for 5 consecutive years, with -$29.5 million as the latest value for Q1 2026.

  • For Q1 2026, EBT rose 68.67% year-over-year to -$29.5 million; the TTM value through Mar 2026 reached -$156.3 million, up 54.8%, while the annual FY2025 figure was -$221.1 million, 33.88% up from the prior year.
  • EBT hit -$29.5 million in Q1 2026 for Phathom Pharmaceuticals, down from -$21.1 million in the prior quarter.
  • Across five years, EBT topped out at -$21.1 million in Q4 2025 and bottomed at -$94.3 million in Q1 2025.
  • Average EBT over 5 years is -$57.9 million, with a median of -$51.1 million recorded in 2022.
  • Year-over-year, EBT plummeted 123.2% in 2024 and then skyrocketed 71.62% in 2025.
  • Phathom Pharmaceuticals' EBT stood at -$55.0 million in 2022, then crashed by 44.76% to -$79.6 million in 2023, then grew by 6.36% to -$74.5 million in 2024, then surged by 71.62% to -$21.1 million in 2025, then tumbled by 39.71% to -$29.5 million in 2026.
  • According to Business Quant data, EBT over the past three periods came in at -$29.5 million, -$21.1 million, and -$30.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.